Stem Cell Authority Stock Shares Outstanding
| SCAL Stock | USD 0.01 0.00 0.00% |
Stem Cell Authority fundamentals help investors to digest information that contributes to Stem Cell's financial success or failures. It also enables traders to predict the movement of Stem Pink Sheet. The fundamental analysis module provides a way to measure Stem Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Stem Cell pink sheet.
Stem |
Stem Cell Authority Company Shares Outstanding Analysis
Stem Cell's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Stem Cell Shares Outstanding | 348.71 M |
Most of Stem Cell's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Stem Cell Authority is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Stem Cell Authority has 348.71 M of shares currently outstending. This is 93.15% higher than that of the Healthcare sector and significantly higher than that of the Medical Care Facilities industry. The shares outstanding for all United States stocks is 39.02% higher than that of the company.
Stem Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stem Cell's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Stem Cell could also be used in its relative valuation, which is a method of valuing Stem Cell by comparing valuation metrics of similar companies.Stem Cell is currently under evaluation in shares outstanding category among its peers.
Stem Fundamentals
| Return On Asset | 0.49 | |||
| Profit Margin | 0.55 % | |||
| Operating Margin | 0.55 % | |||
| Current Valuation | 9.15 M | |||
| Shares Outstanding | 348.71 M | |||
| Price To Earning | 2.00 X | |||
| Price To Sales | 1.05 X | |||
| Revenue | 3.33 M | |||
| Gross Profit | 2.27 M | |||
| Net Income | 1.83 M | |||
| Cash And Equivalents | 39.84 K | |||
| Total Debt | 675.1 K | |||
| Debt To Equity | 4.88 % | |||
| Current Ratio | 1.12 X | |||
| Earnings Per Share | 0.01 X | |||
| Beta | -71.45 | |||
| Market Capitalization | 2.34 M | |||
| Total Asset | 3.99 M | |||
| Z Score | 1.8 | |||
| Net Asset | 3.99 M |
About Stem Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stem Cell Authority's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stem Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stem Cell Authority based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Stem Pink Sheet
Stem Cell financial ratios help investors to determine whether Stem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stem with respect to the benefits of owning Stem Cell security.